TY - JOUR T1 - 18F-Alfatide PET versus 18F-FDG PET Imaging in LLC Tumor-Bearing C57BL/6 Mice Model: A Comparative Analysis JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1364 LP - 1364 VL - 57 IS - supplement 2 AU - Yu-Chun Wei AU - Yongsheng Gao AU - Jianbo Zhang AU - Zheng Fu AU - Xudong Hu AU - Wenhong Hou AU - Hui Zhang AU - Jinming Yu AU - Shuanghu Yuan Y1 - 2016/05/01 UR - http://jnm.snmjournals.org/content/57/supplement_2/1364.abstract N2 - 1364Objectives Tumor detection depends on the contrast between tumor activity and background activity. Although glycolytic metabolism imaging by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is the most widespread application of radiotracers in clinical settings, its tumor background ratio in some organs and some diabetic patients is not sufficiently high enough for a diagnosis. New tracers have been developed as supplements. This study aimed to stereotactically compare the PET imaging performance of 18F-Alfatide (18F-ALF-NOTA-PRGD2, denoted as 18F-Alfatide) and 18F-FDG and immunohistochemistry (IHC) staining in a Lewis lung carcinoma (LLC) tumor-bearing C57BL/6 mouse model.Methods LLC tumor-bearing C57BL/6 mice were investigated by PET imaging using 18F-Alfatide and 18F-FDG separately. 18F-Alfatide standard uptake values (SUVs) and 18F-FDG SUVs were measured in normal tissues, organs and the overall tumor at 1 hour after injection. The PET SUV and αvβ3 and GLUT-1 expression on IHC were further measured and correlated with each other stereotactically when the xenografts were divided into outer (SUVRGD-O, SUVFDG-O), middle (SUVRGD-M, SUVFDG-M) and inner (SUVRGD-I, SUVFDG-I) layers.Results All of the xenografts were detected on both 18F-FDG PET and 18F-Alfatide PET. Although 18F-FDG SUVs were higher than 18F-Alfatide SUVs in tumors, most of the normal tissues and organs except for the bladder, the tumor-to-brain, tumor-to-lung, and tumor-to-heart ratios of 18F-Alfatide PET were significantly higher than those of 18F-FDG PET (P <0.001). The spatial heterogeneity of the tumors was detected, and the tracer accumulation enhanced from the outer layer to the inner layer consistently using the two tracers (SUVFDG-O, SUVFDG-M, and SUVFDG-I were 3.04±0.64, 6.33±1.16, 9.95±1.64, respectively; SUVRGD-O, SUVRGD-M, and SUVRGD-I were 1.46±0.30, 1.96±0.37, 2.36±0.37, respectively; P<0.001). PET imaging was validated by IHC examination. The parameters of the tumors were significantly correlated with each other between 18F-FDG SUVmax and GLUT-1 (R0.895, P0.001), 18F-Alfatide SUVmax and αvβ3 (R0.595, P0.019), 18F-FDG SUVmax and 18F-Alfatide SUVmax (R0.917, P0.001), and GLUT-1 and αvβ3 (R0.637, P0.011).Conclusions 18F-Alfatide PET may be an effective tracer for tumor detection, spatial heterogeneity imaging and an alternative supplement to 18F-FDG PET, particularly for patients with enhanced characteristics in the brain, chest tumors or diabetes, meriting further study. ER -